Leucine-rich repeats and immunoglobulin-like domains protein 1 messenger RNA (LRIG1 mRNA)

Leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) messenger RNA encodes a critical transmembrane protein that serves as a potent negative regulator of several receptor tyrosine kinases (RTKs), including the EGFR family (ErbB1-4), MET, and RET (PMID: 15574778, 22431511). By promoting the ubiquitination and subsequent lysosomal degradation of these receptors, the protein product of LRIG1 mRNA acts as a natural tumor suppressor that limits growth factor-induced cellular proliferation and survival (PMID: 12773391). In many human malignancies, such as glioblastoma, breast cancer, and lung cancer, LRIG1 mRNA expression is frequently downregulated, which contributes to the overactivation of oncogenic signaling pathways and is often associated with poor clinical outcomes (PMID: 23653360, 25622015). Consequently, LRIG1 mRNA is being explored as both a prognostic biomarker and a therapeutic target, with research focusing on strategies to restore its expression to counteract RTK-driven tumor growth. Therapeutic approaches under investigation include the use of viral vectors or synthetic mRNA delivery systems to reintroduce LRIG1 into cancer cells, thereby restoring the homeostatic control of growth factor signaling (PMID: 19176385).

Other names

LRIG1 transcriptLIG1 mRNALeucine-rich repeats and immunoglobulin-like domains protein 1 transcript

Restoration of LRIG1 protein expression to facilitate the ubiquitination and degradation of oncogenic receptor tyrosine kinases (RTKs), thereby inhibiting downstream signaling pathways such as MAPK and PI3K/Akt.